Intuitive Surgical (ISRG)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$427.30-1.28%
Close 2026-07-07 · 1-day change
Reading ISRG? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ISRG free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading ISRG? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ISRG free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on growth in surgical procedures. The current thesis state is intact, supported by strong recent financial performance and management priorities.
The valuation is considered expensive compared to peers, reflecting a durable premium. The market appears to have priced in a slight expectations gap, indicating that some cautious sentiment is already present.
Management is focused on increasing da Vinci procedures, which have shown strong growth. However, maintaining gross profit margins and executing share repurchase programs are mixed in their status, suggesting some challenges ahead.
The thesis hinges on the performance of sector bellwethers like MDLN, BDX, and RMD. If these companies continue to perform well, ISRG may benefit from positive sector momentum, while any negative guidance from them could pose risks.
Overall, ISRG's fundamentals are strong, but the company must navigate sector dynamics and execution challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read. However, a below-consensus forecast may hinder growth in da Vinci procedures. Additionally, there are concerns about gross profit margins.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This growth rate is critical for Intuitive's strategy. A decline signals potential issues in market demand.
Confirms:Q2 2026 da Vinci procedure growth reported below 13.5%.
Disproves:Q2 2026 da Vinci procedure growth reported above 15.5%.
Why it matters: Maintaining profit margins is key for Intuitive's financial health. A drop signals potential cost issues.
Confirms:Gross profit margin reported below 67.5%.
Disproves:Gross profit margin reported above 68.5%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.